A Randomised, Double-Blind, Parallel Group Multicentre Trial to Compare the Efficacy and Safety of Zolmitriptan 2.5 mg, Zolmitriptan 5.0 mg and Sumatriptan 50 mg in the Treatment of Migraine Headache (311CIL/0070 [ZEUS]) (6-Attack Analysis).
Study identifier:311CIL/0070
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomised, Double-Blind, Parallel Group Multicentre Trial to Compare the Efficacy and Safety of Zolmitriptan 2.5 mg, Zolmitriptan 5.0 mg and Sumatriptan 50 mg in the Treatment of Migraine Headache (311CIL/0070 [ZEUS]) (6-Attack Analysis).
Medical condition
migraine
Phase
N/A
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Jan 1997
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
